Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 77

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 77
---
841 At September 30, 2025, there were no investments available for sale that were materially less than their amortized cost.

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  24

The Company elects to recognize its interest receivable separate from its available-for-sale investments. At September 30, 2025 and December 31, 2024, the interest receivable from its available-for-sale investments recognized in prepaid expenses and other current assets was $0.2 million and $0.5 million, respectively.Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term and long-term available-for-sale investments and accounts receivable. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. Such amounts may exceed federally-insured limits. As of September 30, 2025, three wholesalers each accounted for over 10% of the Company’s accounts receivable, at 33%, 22% and 17%. At December 31, 2024, three wholesalers each accounted for over 10% of the Company’s accounts receivable, at 34%, 18% and 16%. For additional information regarding the Company’s wholesalers, see Note 2, Summary of Significant Accounting Policies. EXPAREL and ZILRETTA revenues are primarily derived from major wholesalers and specialty distributors that generally have significant cash resources. The Company performs ongoing credit evaluations of its customers as warranted and generally does not require collateral. Allowances for credit losses on the Company’s accounts receivable are maintained based on historical payment patterns, current and estimated future economic conditions, aging of accounts receivable and its write-off history. As of September 30, 2025 and December 31, 2024, there were $0.6 million and $0.4 million of allowances for credit losses on the Company’s accounts receivable, respectively.

NOTE 11—STOCKHOLDERS’ EQUITY

Accumulated Other Comprehensive IncomeThe following tables illustrate the changes in the balances of the Company’s accumulated other comprehensive income for the periods presented (in thousands):Net Unrealized Gain (Loss) From Available-For-Sale InvestmentsUnrealized Foreign Currency TranslationAccumulated Other Comprehensive IncomeBalance at December 31, 2024$190 $153 $343    Net unrealized loss on investments, net of tax